DTG based ARV regimen without ABC — Competitive Intelligence Brief

DTG based ARV regimen without ABC (DTG based ARV regimen without ABC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease / Virology.

phase 2 Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease / Virology Small molecule

Target snapshot

DTG based ARV regimen without ABC (DTG based ARV regimen without ABC) — ViiV Healthcare. DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DTG based ARV regimen without ABC TARGET	DTG based ARV regimen without ABC	ViiV Healthcare	phase 2	Integrase strand transfer inhibitor (INSTI)	HIV integrase
tenofovir, lamivudine, efavirenz	tenofovir, lamivudine, efavirenz	Bamrasnaradura Infectious Diseases Institute	marketed	Antiretroviral combination therapy (NRTI/NtRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
TRUVADA + Raltegravir	TRUVADA + Raltegravir	Fenway Community Health	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase and HIV integrase
lopinavir/ritonavir and raltegravir	lopinavir/ritonavir and raltegravir	Saint Michael's Medical Center	marketed	Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir)	HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir)
Integrase strand transfer inhibitors	Integrase strand transfer inhibitors	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

1. ViiV Healthcare · 12 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
3. Merck Sharp & Dohme LLC · 5 drugs in this class
4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
7. ANRS, Emerging Infectious Diseases · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. University of Colorado, Denver · 1 drug in this class
10. MU-JHU CARE · 1 drug in this class